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We  investigated  the role  of  Bcl-2  family  proteins  in  human  growth  plate  cartilage  and  human  proliferative  chondrocytes.
Glucocortcoid  (GC)  treatment  induced  Bid  cleavage  and  increased  the levels  of  Bak.
Bid  knockdown  prevented  GC-induced  apoptosis  in  chondrocytes.
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a  b  s  t  r  a  c  t
Glucocorticoids  (GCs)  are  widely  used  to  treat inﬂammatory  diseases  and  cancers.  A multitude  of  unde-
sired side  effects  have  been  reported  in GC-treated  patients  including  decreased  linear  bone  growth.
We  have  previously  reported  that  GCs  activate  the  caspase  cascade  and  trigger  Bax-mediated  mito-
chondrial  apoptosis  in  growth  plate  chondrocytes  causing  growth  retardation  in  young  mice.  To  further
explore  the  role  of  mitochondrial  apoptosis  in  GC-induced  bone  growth  retardation,  a  number  of  pro-
and  anti-apoptotic  proteins  were  studied  in  ex  vivo  cultures  of  human  growth  plate  cartilage  and  human
HCS-2/8  proliferative  chondrocytes  exposed  to dexamethasone.  Dexamethasone  was  found  to increaseuman growth plate
hondrocytes
poptosis
cl-2 family proteins
id
the  pro-apoptotic  proteins  Bcl-xS,  Bad,  and  Bak  as well  as  the proteolysis  of  Bid.  Anti-Bid small  inter-
fering  RNA  partially  rescued  the  chondrocytes  from  dexamethasone-induced  apoptosis.  Taken  together,
our data  suggest  that  GC  treatment  differentially  regulates  Bcl-2  family  member  proteins  to  facilitate
mitochondrial  apoptosis  in  proliferative  chondrocytes  thereby  contributing  to  GC-induced  bone growth
impairment.  Prevention  of this  imbalance  between  pro- and  anti-apoptotic  Bcl-2  family  proteins  may
provide  a new  strategy  to  protect  from  adverse  effects  of  GCs  on  bone  growth.
The A© 2013 
. IntroductionGlucocorticoids (GCs) are small, lipophilic compounds widely
sed in the treatment of autoimmune diseases, inﬂammation and
Abbreviations: GCs, glucocorticoids; Dexa, dexamethasone; Cont, control.∗ Corresponding author at: Pediatric Endocrinology Unit, Q2:08 Karolinska Uni-
ersity Hospital, 171 76 Stockholm, Sweden. Tel.: +46 8 517 72 382;
ax:  +46 8 517 75 128.
E-mail address: Farasat.Zaman@ki.se (F. Zaman).
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cancers. It is estimated that in the UK alone, more than 250,000 peo-
ple are taking systemic steroids for various conditions, whereas 10%
of all children receive some form of GCs treatment under different
conditions (Mushtaq and Ahmed, 2002). GCs not only inhibit the
expression of pro-inﬂammatory cytokines (Amsterdam and Sasson,
2002) but are also reported to trigger apoptosis in a variety of cell
types (Distelhorst, 2002). Unfortunately, the wide use of GCs in chil-
dren is also associated with impaired bone growth (Yeh et al., 2004).
Experimental studies have demonstrated that GCs may  suppress
the GH axis (Lima et al., 1993). Furthermore, we and others have
Open access under CC BY-NC-ND license.reported that GC treatment decreases longitudinal bone growth by
suppressing chondrocyte proliferation, hypertrophy, and cartilage
matrix production. We  have also shown that GCs may trigger unde-
sired chondrocyte apoptosis by activating caspase 8, 9 and 3, along
NC-ND license.
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Fig. 1. Dexamethasone (Dexa) increases Bak levels in human growth plate cartilage. (A) Schematic diagram describing the method of culturing human growth plate biopsies
obtained from children undergoing epiphyseal surgery. A needle is inserted in the growth plate area to collect the growth plate cartilage. (B) Tibia growth plate cartilage
biopsy  as visualized in a dissection microscope after collection. (C) Sectioning of a growth plate biopsy into thin slices using a scalpel. (D) Growth plate cartilage slices are
individually transferred to culture dishes. (E and F) Light microscopy of growth plate slices ﬁxed and stained with van Gieson/Alcian blue. (G) The growth plate biopsies were
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Ireated with Dexa (1 M)  or control medium for 24 h and analyzed for immunoexp
ultured human growth plate cartilage biopsies (n = 5) and (I) in HCS-2/8 chondrocy
ith suppression of the Akt-PI3K signaling pathway (Chrysis et al.,
005). Although experimental data have shown that dexametha-
one (Dexa) treatment may  trigger apoptosis within the growth
late (Chrysis et al., 2005; Mushtaq and Ahmed, 2002; Mushtaq
t al., 2004; Rooman et al., 2003; Smink et al., 2003), the molecular
echanisms of GCs-induced apoptosis and its role in bone growth
mpairment remain elusive. In other tissues, it has been shown that
Cs not only trigger apoptosis but can also suppress pro-survival
ignals including NF-B, Bcl-2 and insulin-like growth factor 1 (IGF-
) (Jha et al., 2009; Nishi et al., 2009). Furthermore, the ratio between
nti- and pro-apoptotic Bcl-2 family members is known to be crit-
cal for the determination of the apoptotic status (Dragovich et al.,
998).
We  recently reported that suppression of the pro-apoptotic
rotein Bax rescues young mice from Dexa-induced growth
etardation (Zaman et al., 2012). In view of the critical role
f Bcl-2 family members for the regulation of apoptosis,
e hypothesized that other pro- and anti-apoptotic proteins
eside Bax may  contribute to Dexa-induced chondrocyte apo-
tosis. To test this, human chondrocytes were exposed to
examethasone and the expression levels of several key Bcl-
 family member proteins were studied. Our ﬁndings further
ur understanding of the regulation of GC-induced apoptosis of
hondrocytes.
. Materials and methods
.1. ReagentsDexamethasone (Dexa) and IGF-I (Sigma–Aldrich, Steinheim, Germany) were
issolved in ethanol or saline, according to the manufacturer’s instructions. Trypsin,
hosphate buffered saline (PBS), fetal bovine serum (FBS), ethylenediaminetetraace-
ic acid (EDTA), MEM  alpha medium, and DMEM/F12 medium were purchased from
nvitrogen (Paisley, Scotland).n of the pro-apoptotic protein Bak. (H) Quantitative analysis of Bak expression in
 = 4, **p < 0.01, ***p < 0.001).
2.2. Culture of human growth plate biopsies
The collection of human growth plate biopsies was  approved by the local human
ethics committee (Karolinska Institutet Research Ethics Committee North at the
Karolinska University Hospital). Informed consent was obtained from all subjects
and  their parents which was documented in the original hospital records. The
biopsies were collected from the tibial growth plates of four tall boys (13–15
years old) who underwent epiphyseal surgery (epiphysiodeses) to reduce their
bone growth (Fig. 1A and B). Immediately after collection, the biopsies were
sliced (Fig. 1C–F) and the slices were transferred into DMEM-F12 medium (phe-
nol  red free) containing gentamycin (10 g/ml), 0.2% bovine serum albumin (BSA),
1  mM betaglycerphosphate, and ascorbic acid (50 g/ml). Biopsies were treated
with Dexa (1 M) or vehicle (99% EtOH) for 24 h. Biopsies were ﬁxed in 4%
formaldehyde, decalciﬁed in 10% EDTA for 24 h at 4 ◦C, and embedded in parafﬁn
blocks.
2.3. Fluorescence microscopy
Human growth plates were cultured for 1 day with and without dexametha-
sone (1 M).  For immunohistochemistry, antigen retrieval was performed in 0.05%
trypsin for 20 min  at 37 ◦C. The sections were incubated with 2.5% normal serum
for  1 h, followed by primary antibody Bak (1:100, Santa Cruz Biotechnology, Santa
Cruz, CA) at 4 ◦C overnight and secondary antibody (1:300) conjugated with FITC
(Molecular Probes Inc., Eugene, Oregon, USA) for 1 h. Slides were counterstained
with DAPI for 15 min at room temperature, and images were captured ﬂuorescence
microscopy (a Nikon E800 ﬁtted with an Olympus DP70 camera).
2.4. Cell culture
Trypsin, phosphate buffer saline (PBS), EDTA, fetal bovine serum (FBS), and
DMEM/F12 medium were all purchased from Invitrogen Life Technologies (Paisley,
Scotland, UK). The human chondrosarcoma-derived chondrocytic cell line, HCS-2/8
(Takigawa et al., 1989), was maintained in D-MEM/F12 medium supplemented with
20% FBS and 20 g/ml gentamycin in humidiﬁed air with 5% CO2. The cells cultured in
ﬂask were sub-cultivated every 5–6 days and replaced with fresh medium. To inves-
tigate the expression of proteins by immunoblotting, cells were seeded in 75-cm2
tissue culture ﬂasks (2 × 106 cells/ﬂask) in DMEM/F12 medium containing 20% FBS.
After 72 h, when cells were approximately 80% conﬂuent, they were washed with
1× PBS and the medium was changed to test medium (DMEM/F-12 supplemented
with 1% FBS).
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.5. Western immunoblotting
Following incubation, HCS-2/8 cells were lysed in RIPA buffer and protein
oncentration was measured using the Bradford assay (Bio-Rad Laboratories
B,  Sundbyberg, Sweden). Cell lysates were subjected to SDS-PAGE, elec-
rophoretically transferred to nitrocellulose membranes as described previously
Fadeel et al., 1999) and subsequently incubated with primary antibodies
gainst Bcl-xS/L (1:1000), Bad (1:1000), Bak (1:1000) and GAPDH (1:1000)
urchased from Santa Cruz Biotechnology, Santa Cruz, CA. Antibodies against
-Bad (1:500) and Bid (1:500) were purchased from (Cell Signaling, CA). The
embranes were incubated overnight at 4 ◦C, washed with 1× TBS-T and incu-
ated with HRP-conjugated secondary antibodies. The signals were detected
sing the ECL-plus chemiluminescence detection system. The images obtained
rom western immunoblots were quantiﬁed by using the “Image J” software
NIH).
.6. DNA fragmentation analysis
The detection and quantiﬁcation of cytoplasmic, histone-associated DNA frag-
ents (Cell Death Detection ELISAPLUS, Roche Diagnostics GmbH, Germany) was
erformed as previously described (Chrysis et al., 2005).
.7. Small-interfering RNAs
Human HCS-2/8 chondrocytic cells in proliferation phase were transfected with
 double-stranded siRNA oligonucleotide designed to interfere with the expression
f  human Bid (Santa Cruz Biotechnology), as previously described (Zaman et al.,
007).
.8. TUNEL assay
Apoptotic cells were identiﬁed by terminal deoxynucleotidyl transferase (TdT)-
ediated deoxy-UTP nick end labeling (TUNEL) by using a DNA fragmentation kit
Oncogene Research, Boston, MA)  and digital automatic cell counting was performed
s  previously described (Zaman et al., 2007)..9. Statistical analysis
All data are presented as mean values ± SEM. Differences between groups were
ested using one-way analysis of variance (ANOVA) followed by the Holm–Sidak
ost-hoc test.
ig. 2. Dexamethasone (Dexa) induces Bid cleavage and Bid-siRNA prevents Dexa-induce
nd  IGF-I (100 ng/ml) for 72 h. (A) HCS-2/8 proliferative chondrocytes were lysed and subj
leaved fragment). n = 3, ***p < 0.001 vs., control. (B) HCS-2/8 proliferative chondrocytes 
25  M) for 72 h. The cells were then analyzed for apoptosis by using a cell death detectio
roliferative chondrocytes were transfected with a Bid-speciﬁc siRNA for 48 h and analyz
CS-2/8 proliferative chondrocytes transfected with Bid-siRNA were subjected to westerers 224 (2014) 196– 200
3. Results and discussion
We  have recently reported that ablation of Bax protects mice
from GC-induced bone growth impairment (Zaman et al., 2012).
Nevertheless, Bax-deﬁcient male mice were found to be less pro-
tected from GC treatment. Therefore, in this study we decided to
expand our investigation to other Bcl-2 family proteins for their
potential involvement to regulate the toxic effects of dexametha-
sone in chondrocytes. In addition to Bax, the pro-apoptotic proteins
Bid and Bak are also important mediators of mitochondrial apo-
ptosis (Wei  et al., 2001). Whether these pro-apoptotic proteins
are involved in GC-induced chondrocyte apoptosis in chondro-
cytes is unknown. In the present study, using an established model
of cultured human growth plate cartilage and cultured human
HCS 2/8 chondrocytes, we explored the role of these proteins in
GC-induced chondrocyte apoptosis. We  previously reported that
dexamethasone induces activation of caspase-8 (Chrysis et al.,
2005). Caspase-8 activation is often associated with cleavage of the
pro-apoptotic protein Bid (Luo et al., 1998). Under normal phys-
iological conditions, Bid is present in the cytosol of cells in an
inactive state. However, upon proteolytic cleavage, Bid becomes
active, inserts into the mitochondrial outer membrane, and causes
mitochondrial membrane injury, contributing to the apoptotic cas-
cade in the cell. Bid is therefore one additional potential mediator
of the pro-apoptotic effects of GCs, in addition to Bax.
3.1. Dexamethasone increases Bak levels in human growth plate
cartilage
We  ﬁrst measured the levels of the pro-apoptotic protein
Bak in human growth plate cartilage (Fig. 1G) specimens treated
with dexamethasone (1 M)  for 24 h and then found that Bak
was signiﬁcantly increased (p < 0.01 vs. control; Fig. 1H). Further,
HCS-2/8 chondrocytes also displayed signiﬁcant increases in the
d apoptosis. HCS-2/8 proliferative chondrocytes were cultured with Dexa (25 M)
ected to western immunoblotting to investigate the cleavage of Bid (full length and
were transfected with a Bid-speciﬁc siRNA for 48 h prior to incubation with Dexa
n ELISA kit. n = 5, *p < 0.05, ***p < 0.001. (C) To verify the suppression of Bid, HCS-2/8
ed for silencing of full length Bid by western immunoblotting. (D) Cell lysates from
n immunoblotting to investigate the Bak levels, n = 4, ***p < 0.001 vs., control.
F. Zaman et al. / Toxicology Letters 224 (2014) 196– 200 199
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reated with Dexa (25 M)  and/or IGF-I (100 ng/ml) for 72 h, lysed and then subjec
n  = 4) and (C) P-Bad (Ser136), n = 4. *p < 0.05, **p  < 0.01, ***p < 0.001.
evels of Bak (p < 0.001 vs. control; Fig. 1I). It has previously been
eported that Bid can directly activate Bak in kidney cells thereby
ensitizing these cells to apoptosis by inhibiting Bcl-2/Bax inter-
ction (Moreau et al., 2003; Letai et al., 2002). Altogether, this
ed us to investigate the role of Bid in GC-induced chondrocyte
poptosis.
.2. Silencing of Bid affords partial protection against
examethasone-induced apoptosis
Proliferative human HCS-2/8 chondrocytes were exposed to
examethasone (25 mol/L) for 72 h and protein extracts sub-
ected to Western immunoblotting. We  could then detect Bid
leavage, suggesting activation of Bid, in dexamethasone treated
ells but not in control (Fig. 2A). To verify any role of Bid in
examethasone-induced chondrocyte apoptosis, human HCS-2/8
hondrocytes were transfected with selective siRNA-Bid. Interest-
ngly, we then observed apoptosis to be partially rescued when
xposed to dexamethasone (p < 0.05; Fig. 2B). When compared
o control, apoptosis was increased by 58% in cells exposed to
examethasone alone while only 31% in those co-incubated with
iRNA-Bid + dexamethasone (Fig. 2B and C). In contrast, dexameth-
sone induced cleavage of Bid (p < 0.001 vs. control) which could
ot be prevented by the anti-apoptotic protein IGF-I (Fig. 2A).
urther, we observed that Bid-siRNA signiﬁcantly decreased Bak
evels (p < 0.05 vs. Dexa alone) in HCS-2/8 proliferative chondro-
ytes when treated with dexamethasone (Fig. 2D). Our ﬁnding
hat dexamethasone-induced chondrocyte apoptosis can be pre-
ented by suppressing Bid suggests a physiological role of this
rotein in apoptotic signaling upon treatment of these cells with
Cs. Bad (P-Bad) in proliferative chondrocytes. HCS proliferative chondrocytes were
 Western blotting for quantitative analysis of (A) Bcl-xS and Bcl-xL (n = 4), (B) Bad
3.3. Dexamethasone increases Bcl-xS and Bad in proliferative
chondrocytes
Based on our ﬁnding that dexamethasone induces Bid cleavage,
we hypothesized that GC treatment may  inﬂuence the levels of pro-
and anti-survival factors known to affect mitochondrial integrity.
We  indeed observed that dexamethasone (25 mol/L) treatment
increased the levels of Bcl-xS by 68% (p < 0.01 vs. control; Fig. 3A),
an effect which was  prevented by the co-incubation with IGF-I
(100 ng/ml) (p < 0.01 vs. Dexa alone; Fig. 3A). The expression levels
of Bcl-xL was however not signiﬁcantly affected (Fig. 3A). Next step
was to assess Bad, a downstream effector of Akt, which is crucial for
the activation of caspase-9 and -3. In dexamethasone treated cells, a
signiﬁcant increase in the total level of Bad was detected (p < 0.001
vs. control) whereas co-administration with IGF-I clearly prevented
this increase (p < 0.01 vs. Dexa alone; Fig. 3B). In contrast, dexa-
methasone suppressed phosphorylation of Bad (Ser136) by 57%
(p < 0.01 vs. control) whereas co-incubation with IGF-I and dexa-
methasone signiﬁcantly increased Bad phosphorylation (p < 0.05
vs. Dexa alone; Fig. 3C). These ﬁndings are of particular interest as
phosphorylation of Bad on Ser136 is known to prevent apoptosis
(Jeong et al., 2008). Altogether, our data show that dexametha-
sone treatment increases Bcl-xS and total Bad while decreasing
Bcl-xL levels. Bcl-xS (pro-apoptotic) is a shorter version of Bcl-
xL (anti-apoptotic) which has been proposed to act through a
novel mechanism to induce cell death without activating caspases
(Fridman et al., 2001). Bcl-xS, mainly found in cells with a high
rate of proliferation, inhibits the anti-apoptotic effects of Bcl-xL and
Bcl-2. In contrast, Bcl-xL over-expression is capable to protect from
apoptosis (Blanco-Colio et al., 2003). The previously reported data
are in line with the observed effects of dexamethasone on these
proteins in human chondrocytes reported here.
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. Conclusions
Our data demonstrate that GC treatment causes an imbalance
etween pro- and anti-apoptotic Bcl-2 family proteins and that
peciﬁc targeting of Bid prevents GC-induced apoptosis in human
hondrocytes. These ﬁndings, in conjunction with previous studies
Zaman et al., 2012), further our understanding of the regulation
f apoptosis in chondrocytes exposed to GC. This work could open
or new strategies rescuing longitudinal bone growth in GC-treated
hildren by speciﬁcally targeting mitochondrial proteins.
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